凯信远达上涨51.16%，报1.95美元/股，总市值3021.07万美元

Group 1 - The stock price of CASI Pharmaceuticals (凯信远达) opened at $1.95 per share, reflecting a significant increase of 51.16% as of 21:30, with a total trading volume of $133 million and a market capitalization of $30.21 million [1] - As of March 31, 2025, CASI reported total revenue of $6.24 million, representing a year-over-year growth of 83.04%, while the net profit attributable to shareholders was -$10.75 million, a decrease of 12.83% compared to the previous year [1] Group 2 - CASI Pharmaceuticals is scheduled to disclose its mid-year report for the fiscal year 2025 on August 15, with the actual disclosure date subject to the company's announcement [2] - The company is a NASDAQ-listed biopharmaceutical firm based in Rockville, Maryland, focused on providing advanced treatment solutions for blood cancers in China, with subsidiaries in Beijing and a joint venture and R&D center in Wuxi [2] - CASI's product and research pipeline covers multiple disease areas, including multiple myeloma, B-cell non-Hodgkin lymphoma, and acute lymphoblastic leukemia [2]